111 related articles for article (PubMed ID: 9137413)
21. In vitro cytotoxic effect of new diphenylphosphinoethane-copper(I) complexes on human ovarian carcinoma cells.
Adwankar MK; Wycliff C; Samuelson A
Indian J Exp Biol; 1997 Aug; 35(8):810-4. PubMed ID: 9475052
[TBL] [Abstract][Full Text] [Related]
22. Treatment with paclitaxel alone rather than combination with paclitaxel and cisplatin may be selective for cisplatin-resistant ovarian carcinoma.
Yamamoto K; Kikuchi Y; Kudoh K; Hirata J; Kita T; Nagata I
Jpn J Clin Oncol; 2000 Oct; 30(10):446-9. PubMed ID: 11185891
[TBL] [Abstract][Full Text] [Related]
23. [Comparative studies of the antitumor activities of CDDP and the analogs--using gynecological carcinomas transplanted into nude mice].
Suzumori K; Yasui Y; Suzumori K; Yagami Y
Gan To Kagaku Ryoho; 1989 Mar; 16(3 Pt 1):387-91. PubMed ID: 2649007
[TBL] [Abstract][Full Text] [Related]
24. Carboplatin plus paclitaxel as first-line chemotherapy in previously untreated advanced ovarian cancer. German AGO Study Group Ovarian Cancer. Arbeitsgemeinschaft Gynäkologische Onkologie.
du Bois A; Lück HJ; Meier W; Möbus V; Costa S; Richter B; Bauknecht T; Warm M; Schroeder W; Olbricht S; Nitz U; Jackisch C
Semin Oncol; 1997 Aug; 24(4 Suppl 11):S11-28-S11-33. PubMed ID: 9314296
[TBL] [Abstract][Full Text] [Related]
25. Experimental characterization of recurrent ovarian immature teratoma cells after optimal surgery.
Tanaka T; Toujima S; Utsunomiya T; Yukawa K; Umesaki N
Oncol Rep; 2008 Jul; 20(1):13-23. PubMed ID: 18575713
[TBL] [Abstract][Full Text] [Related]
26. Effects of mitomycin C and carboplatin pretreatment on multidrug resistance-associated P-glycoprotein expression and on subsequent suppression of tumor growth by doxorubicin and paclitaxel in human metastatic breast cancer xenografted nude mice.
Ihnat MA; Nervi AM; Anthony SP; Kaltreider RC; Warren AJ; Pesce CA; Davis SA; Lariviere JP; Hamilton JW
Oncol Res; 1999; 11(7):303-10. PubMed ID: 10757444
[TBL] [Abstract][Full Text] [Related]
27. Preclinical antitumor activity of the oral platinum analog satraplatin.
Wosikowski K; Lamphere L; Unteregger G; Jung V; Kaplan F; Xu JP; Rattel B; Caligiuri M
Cancer Chemother Pharmacol; 2007 Sep; 60(4):589-600. PubMed ID: 17541592
[TBL] [Abstract][Full Text] [Related]
28. Novel mechanisms of platinum drug resistance identified in cells selected for resistance to JM118 the active metabolite of satraplatin.
Samimi G; Kishimoto S; Manorek G; Breaux JK; Howell SB
Cancer Chemother Pharmacol; 2007 Feb; 59(3):301-12. PubMed ID: 16770583
[TBL] [Abstract][Full Text] [Related]
29. Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs.
Pietras RJ; Pegram MD; Finn RS; Maneval DA; Slamon DJ
Oncogene; 1998 Oct; 17(17):2235-49. PubMed ID: 9811454
[TBL] [Abstract][Full Text] [Related]
30. [Antitumor effect of JM-8 (a cisplatin analogue) on testicular cancer cells in vitro and in vivo].
Hashimura T; Okada K; Yoshida O
Gan To Kagaku Ryoho; 1985 May; 12(5):1137-42. PubMed ID: 3888118
[TBL] [Abstract][Full Text] [Related]
31. Cytotoxic activity of some gold(III) complexes.
Cossu F; Matovic Z; Radanovic D; Ponticelli G
Farmaco; 1994 Apr; 49(4):301-2. PubMed ID: 8049012
[TBL] [Abstract][Full Text] [Related]
32. Antitumor metallocenes: new developments and toxicologic features.
Köpf-Maier P; Köpf H
Anticancer Res; 1986; 6(2):227-33. PubMed ID: 3707060
[TBL] [Abstract][Full Text] [Related]
33. The activity of N-(hydroxymethyl) melamines in fresh human ovarian tumour cells and xenografts.
Coley HM; Jarman M; Jones M; Sargent JM; Kubota T; Lee NC; Goddard PM; Elgie AW; Williamson C; Taylor CG; Judson IR
Anticancer Res; 1996; 16(4A):1851-5. PubMed ID: 8712712
[TBL] [Abstract][Full Text] [Related]
34. In vitro activity of titanocenedichloride versus cisplatin and doxorubicin in primary and recurrent epithelial ovarian cancer.
Kurbacher CM; Mallmann P; Kurbacher JA; Sass G; Andreotti PE; Rahmun A; Hübner H; Krebs D
Anticancer Res; 1994; 14(5A):1961-5. PubMed ID: 7847834
[TBL] [Abstract][Full Text] [Related]
35. [Antitumor activity of platinum analogs against human ovarian tumors heterotransplanted into nude mice].
Sawada M; Ozaki M; Hongo J; Hirota Y; Inagaki M; Taniguchi H; Tateishi R; Mori Y
Gan To Kagaku Ryoho; 1987 Mar; 14(3 Pt 1):693-8. PubMed ID: 3548596
[TBL] [Abstract][Full Text] [Related]
36. Titanocendichloride activity in cisplatin and doxorubicin-resistant human ovarian carcinoma cell lines.
Harstrick A; Schmoll HJ; Sass G; Poliwoda H; Rustum Y
Eur J Cancer; 1993; 29A(7):1000-2. PubMed ID: 8499130
[TBL] [Abstract][Full Text] [Related]
37. [Antitumor effect of carboplatin and iproplatin on human urinary bladder and prostatic cancers grown in nude mice].
Hasegawa J; Kawamura N; Yamada S; Tsuboi N; Akimoto M
Gan To Kagaku Ryoho; 1987 Dec; 14(12):3279-83. PubMed ID: 3318705
[TBL] [Abstract][Full Text] [Related]
38. Antitumor activity of diethynylfluorene derivatives of gold(I).
Chui CH; Wong RS; Gambari R; Cheng GY; Yuen MC; Chan KW; Tong SW; Lau FY; Lai PB; Lam KH; Ho CL; Kan CW; Leung KS; Wong WY
Bioorg Med Chem; 2009 Dec; 17(23):7872-7. PubMed ID: 19889546
[TBL] [Abstract][Full Text] [Related]
39. Sensitization by interleukin-1alpha of carboplatinum anti-tumor activity against human ovarian (NIH:OVCAR-3) carcinoma cells in vitro and in vivo.
Wang Z; Lee KB; Reed E; Sinha BK
Int J Cancer; 1996 Nov; 68(5):583-7. PubMed ID: 8938138
[TBL] [Abstract][Full Text] [Related]
40. [Comparative characteristics of the efficacy of cisplatin and carboplatin in relation to human primary ovarian cancer cells].
Sviridova IK; Sergeeva NS; Chissov VI; Kirsanova VA; Babarina AV; Novikova EG; Obrubova GA
Biull Eksp Biol Med; 1995 Aug; 120(8):208-10. PubMed ID: 7579288
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
